STEP 319: Serum Cardiac Markers and Their Role in the Evaluation of the Patient With Chest Pain (CE: 1.0)
The use of serum markers in the patient with chest pain (CP) was first demonstrated in the 1950s, first the SGOT (now referred to as AST) and then LDH (LD). Both these assays measured the amount of enzyme in the serum that had been released from the tissue. Such was the situation until the early 1960s when CK (CPK) was introduced as a better marker. Therefore, measuring both CK (or total CK) and the MB fraction and calculating the percent of the two improved the laboratory’s role in assessing the CP patient. This article compares the various markers available to test for cardiac damage in patients with chest pain.
- Discuss markers that have been proposed as indicators of risk for cardiac cell damage
- Discuss the use of serum markers
- Reflect on case examples of serum markers